Interestingly, combination therapy involving IL-10/Fc fusion protein and either ICI or chimeric antigen receptor (CAR) T-cell therapy has effectively reinvigorated terminally exhausted CD8+ TILs and demonstrated substantial tumor regression in mice with syngeneic models of melanoma, ovarian, and colorectal carcinoma [65]. This evidence concerns the gene IL10 and melanoma.